Spots Global Cancer Trial Database for vyxeos
Every month we try and update this database with for vyxeos cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | NCT03826992 | Leukemia | Vyxeos Venetoclax | 1 Year - 39 Years | Children's Hospital Medical Center, Cincinnati | |
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | NCT05558124 | Acute Myeloid L... | Vyxeos Gemtuzumab Ozog... | 18 Years - 70 Years | H. Lee Moffitt Cancer Center and Research Institute | |
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | NCT03826992 | Leukemia | Vyxeos Venetoclax | 1 Year - 39 Years | Children's Hospital Medical Center, Cincinnati | |
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | NCT02533115 | Secondary AML | CPX-351 | 60 Years - 75 Years | Jazz Pharmaceuticals | |
Vyxeos for Induction of Low- or Intermediate-risk. | NCT05599360 | Leukemia, Myelo... | Vyxeos Mylotarg | 18 Years - 70 Years | Shaare Zedek Medical Center |